Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World LEIDEN, The ...

Leiden, the Netherlands (July 8, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Crucell and sanofi pasteur reached an ...

Leiden, The Netherlands, 7 January 2009 - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today confirms that it is in friendly discussions with Wyeth that ...

U.S. healthcare giant Johnson & Johnson (NYSE:JNJ) has launched a $2.3 billion bid to takeover vaccine maker Crucell in an effort to catapult itself into the global vaccine market. Through its newly ...

AMSTERDAM -- Johnson & Johnson said Friday it is in advanced talks to acquire Dutch biotech company Crucell NV for $2.29 billion, a deal that would boost the American health care product maker's ...

Van Herk Groep has taken note of the announcement of 6 October 2010 that Johnson & Johnson (J&J) and the board of Crucell have reached agreement on J&J making a bid. Van Herk Groep has been a Crucell ...

LEIDEN, The Netherlands, July 29, 2009 – The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), ...

AMSTERDAM, Aug 17 (Reuters) - Dutch biotech group Crucell swung to a second-quarter net profit as it benefited from production problems at one of its key rivals, and it raised its full-year guidance ...

* Expects to enter development contracts with governments * Fast-track designation hinges on level of flu virus threat * Technology could cut cost of making antibodies By Aaron Gray-Block AMSTERDAM, ...

Total awards for DTwP-HepB-Hib vaccine launched in 2006 now exceed $900M. Crucell landed a $110 million contract with UNICEF to supply Quinvaxem®, its pediatric vaccine, to the developing world.

TRENTON, N.J. -- Johnson & Johnson said Wednesday it is buying Holland's Crucell NV for about $2.41 billion, marking the American health care giant's latest effort to gain a big foothold in the ...

Dutch biotechnology company Crucell has suffered a blow to its near-term product pipeline after calling time on Aerugen, a vaccine candidate for treating bacterial infections in patients with cystic ...